Pulse Pharmaceuticals receives approval from India’s DCGI for a nano-carrier entrapped vitamin D3 oral dispersion delivery platform. The company says the formulation is designed to deliver vitamin D3 in an oral dispersible form using a nanoparticle-based carrier system.
The approval is reported by multiple outlets as a regulatory milestone for Pulse Pharmaceuticals’ vitamin D3 product platform. While the coverage is broadly consistent on the approval and the basic product description, the outlets provide limited additional detail beyond the DCGI nod and the delivery approach. Differences, where present, are mainly in phrasing—such as whether it is described as “nano-carrier entrapped” or as a “nano vitamin D3 oral dispersion delivery platform”—rather than in the underlying facts of approval and intended administration route.
The announcement frames the DCGI approval as enabling further progression of the product under India’s regulatory pathway. Additional specifics such as commercial timeline, dosage, and scale of manufacturing are not included in the provided summaries.
